FDA Approves Risankizumab (Skyrizi) for Crohn’s Disease

The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019.
FDA Approvals

Leave a Reply

Your email address will not be published.